In addition, Gong et al. [16] found that TMED2 is an oncogene and a potential target for the treatment of epithelial ovarian cancer, while TMED2 increases the expression of IGF1R by competing with miR-30a. This evidence concerns the gene IGF1R and ovarian carcinoma.